Vetter Pharma-Fertigung GmbH has been granted approval by the Food and Drug Administration for the production of a new client drug. Vetter, which provides contract manufacturing services for pharmaceutical and biotech companies, will now begin filling an innovative drug at its Ravensburg Vetter South (RVS) facility. The latest FDA client product approval underscores the competence of the world leader in aseptically pre-filled injection systems used in the production of biotechnological and complex medications.

“For us, the approval by the food and drug administration is a vital step in our corporate development,” said Thomas Otto, Vetter’s Managing Director. “It means that we can continue expanding our business. It also secures our jobs, our investments and our future projects. In addition, it reinforces our position as an expert in the filling of sensitive substances.” Vetter currently has a staff of about 1,900. The company works for numerous international pharmaceutical and biotech firms. Vetter has already passed several FDA inspections with excellent marks.